Mercer Global Advisors
ALXO icon

Mercer Global Advisors’s ALX Oncology ALXO Stock Holding History

Mercer Global Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,077
Closed -$6.28K – 2257
2025
Q1 		$6.28K Buy
+10,077
New +$12.1K ﹤0.01% 2143

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mercer Global Advisors's ALXO Position: Q2 2025 in Review

Mercer Global Advisors sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 10,077 shares — an estimated $6.28K sold.

Mercer Global Advisors first reported a position in ALXO in Q1 2025 and held it in 1 quarter. The position peaked at $6.28K in Q1 2025. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • Mercer Global Advisors reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 10,077 ALX Oncology shares in Q2 2025, an estimated $6.28K.
  • Mercer Global Advisors first reported a position in ALX Oncology in Q1 2025 and held it in 1 quarter.
  • Mercer Global Advisors's ALX Oncology position peaked at $6.28K in Q1 2025.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on Mercer Global Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.